These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 887504)

  • 21. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.
    Green AR; Youdim MB
    Br J Pharmacol; 1975 Nov; 55(3):415-22. PubMed ID: 1203627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A model for the selective mode of action of the irreversible monoamine oxidase inhibitors clorgyline and deprenyl, based on studies of their ability to activate a Ca2+--Mg2+ ATPase in defined lipid environments.
    Houslay MD
    J Pharm Pharmacol; 1977 Nov; 29(11):664-9. PubMed ID: 22599
    [No Abstract]   [Full Text] [Related]  

  • 23. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation.
    Braestrup C; Andersen H; Randrup A
    Eur J Pharmacol; 1975 Nov; 34(1):181-7. PubMed ID: 1241962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of clorgyline and (-)deprenyl on the deamination of normetanephrine and noradrenaline in strips and homogenates of the canine saphenous vein.
    Caramona MM; Osswald W
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Feb; 328(4):396-400. PubMed ID: 3921855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of clorgyline and deprenil on corticosterone levels in rats.
    Ventura MA
    Eur J Pharmacol; 1982 Jul; 81(3):349-55. PubMed ID: 6214412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-methamphetamine and selective MAO inhibitors decrease morphine-reinforced and non-reinforced behavior in rats; Insights towards selegiline's mechanism of action.
    He S; Grasing K
    Pharmacol Biochem Behav; 2006 Dec; 85(4):675-88. PubMed ID: 17157368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of monoamine oxidase by clorgyline and deprenyl in circumventricular structures of rat brain.
    Kinemuchi H; Wakui Y; Arai Y; Kamijo K
    Biochem Pharmacol; 1980 Oct; 29(20):2871-4. PubMed ID: 6776962
    [No Abstract]   [Full Text] [Related]  

  • 29. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons.
    Demarest KT; Smith DJ; Azzaro AJ
    J Pharmacol Exp Ther; 1980 Nov; 215(2):461-8. PubMed ID: 7441510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    Knoll J
    J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonin depression of local cerebral glucose utilisation after monoamine oxidase inhibition.
    Grome JJ; Harper AM
    J Cereb Blood Flow Metab; 1985 Sep; 5(3):473-5. PubMed ID: 4030926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of lithium on phenylethylamine behavior in rats are counteracted by monoamine oxidase A and B inhibitors.
    Smith DF
    Arch Int Pharmacodyn Ther; 1978 Jun; 233(2):221-6. PubMed ID: 567462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic clorgyline and pargyline increase apomorphine-induced stereotypy in the rat.
    Campbell IC; Durcan MJ; Cohen RM; Pickar D; Chugani D; Murphy DL
    Pharmacol Biochem Behav; 1985 Dec; 23(6):921-5. PubMed ID: 4080777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regional inhibition of monoamine oxidase activity by administration of clorgyline in rat brain.
    Kunimoto N; Hazama H; Kamase H; Mizukawa R
    Folia Psychiatr Neurol Jpn; 1983; 37(1):101-5. PubMed ID: 6884911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of chronic clorgyline and amfonelic acid on desensitization of striatal dopamine receptors.
    Meller E; Bohmaker K; Friedhoff AJ
    Life Sci; 1984 Oct; 35(18):1829-38. PubMed ID: 6492992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased total activity in the rat after L-tryptophan plus the monoamine oxidase-A inhibitor amiflamine but not after L-tryptophan plus clorgyline.
    Archer T; Fowler CJ; Fredriksson A; Lewander T; Magnusson O; Mohringe B; Söderberg U
    Br J Pharmacol; 1985 Jul; 85(3):581-90. PubMed ID: 2411326
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The monoamine oxidase inhibitors clorgyline and L-deprenyl also affect the uptake of dopamine, noradrenaline and serotonin by rat brain synaptosomal preparations.
    Lai JC; Leung TK; Guest JF; Lim L; Davison AN
    Biochem Pharmacol; 1980 Oct; 29(20):2763-7. PubMed ID: 6776961
    [No Abstract]   [Full Text] [Related]  

  • 38. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat.
    Dyck LE; Boulton AA
    Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MAO inhibition and the effects of centrally administered LSD, serotonin, and 5-methoxytryptamine on the conditioned avoidance response in rats.
    Prozialeck WC; Vogel WH
    Psychopharmacology (Berl); 1979 Feb; 60(3):309-10. PubMed ID: 108709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions.
    Maragos WF; Tillman PA; Chesnut MD; Jakel RJ
    Brain Res; 1999 Jul; 834(1-2):168-72. PubMed ID: 10407109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.